Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at BTIG Research.
Humacyte: Positive News For Symvess At Last, But Long-Term Threats Persist [Seeking Alpha]
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels
Humacyte (NASDAQ:HUMA) had its price target lowered by analysts at Benchmark Co. from $11.00 to $10.00. They now have a "buy" rating on the stock.